Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations - Slideshow (NASDAQ:CNTB) 2026-09-30
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
Connect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart...